LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis

Equality considerations

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others.

No equality issues were identified related to the use of LIVERFASt. LIVERFASt has not been validated for use in people with acute hepatitis or after a liver transplant. It is also contraindicated in people with comorbidities that could interfere with blood biomarker levels such as chronic haemolytic anaemia and acute inflammatory syndrome.

The risk of liver disease may be higher in people from Black African, Caribbean and South Asian family backgrounds. Liver cirrhosis can be chronic and may affect a person's ability to do their normal day-to-day activities. Race and disability are protected characteristics under the Equality Act 2010.